MyChesCo on MSN1d
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments
WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company ...
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company ...
Concord Biotech invests $10 lakh in Palvella Therapeutics
Concord Biotech Ltd on Thursday said it has invested USD 10 lakh (nearly Rs 85 crore) in US-based Palvella Therapeutics, Inc ...
Pieris Pharmaceuticals Announces Merger and Share Increase
Pieris Pharmaceuticals ( (PIRS) ) has shared an announcement.
Eagle-Tribune1mon
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™
Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients ...
money.rediff4d
Concord Biotech Invests in Palvella Therapeutics for Rare Skin Disease Drug
Concord Biotech invests USD 10 lakh in Palvella Therapeutics to manufacture and commercialize 'Qtorin', a drug for rare genetic skin diseases. The investment will strengthen their partnership and ...
Yle12d
Tuomo Pirttimaan kolumni: Olisin halunnut palvella sellaisessa armeijassa, josta lapseni kertoo inttijuttunsa
Inhoan maailmaa joka pakottaa maanpuolustustahdon esiin lapseni sukupolvesta. Ihailen että heissä sitä on, Pirttimaa ...